Affordable Access

deepdyve-link
Publisher Website

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.

Authors
  • Shah, Vallari1
  • Sherborne, Amy L1
  • Johnson, David C1
  • Ellis, Sidra1
  • Price, Amy1
  • Chowdhury, Farzana1
  • Kendall, Jack1
  • Jenner, Matthew W2
  • Drayson, Mark T3
  • Owen, Roger G4
  • Gregory, Walter M5
  • Morgan, Gareth J6
  • Davies, Faith E6
  • Cook, Gordon7
  • Cairns, David A5
  • Houlston, Richard S1, 8
  • Jackson, Graham9
  • Kaiser, Martin F10
  • 1 Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • 2 Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • 3 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • 4 Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK. , (Mali)
  • 5 Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
  • 6 Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
  • 7 Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • 8 Molecular and Population Genetics, The Institute of Cancer Research, London, UK.
  • 9 Department of Haematology, University of Newcastle, Newcastle Upon Tyne, UK.
  • 10 Division of Molecular Pathology, The Institute of Cancer Research, London, UK. [email protected]
Type
Published Article
Journal
Leukemia
Publisher
Springer Nature
Publication Date
Nov 01, 2020
Volume
34
Issue
11
Pages
3091–3096
Identifiers
DOI: 10.1038/s41375-020-0750-z
PMID: 32157174
Source
Medline
Language
English
License
Unknown
Report this publication

Statistics

Seen <100 times